Skip to content

Warby Parker WRBY Deferred Tax Assets, Operating Loss Carryforwards

Deferred Tax Assets, Operating Loss Carryforwards at other companies

Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
HRO
HarrowHROW

Other financials

Income statement

See full
Revenue$242.4M+8.3%
Gross profit$131.0M+4.0%
Operating income$1.7M-32.5%
Net income$3.2M-8.5%
EPS (diluted)$0.030.0%

Balance sheet

See full
Cash & equivalents$288.2M+8.7%
Total debt$237.6M+6.2%
Total equity$375.8M+6.1%
Total assets$736.4M+7.9%

Cash flow

See full
Operating cash flow$24.5M-16.5%
CapEx$16.1M-0.1%
Free cash flow$8.4M-36.6%

Valuation

See full
Market cap$3.15B+17.1%

Profitability

See full
Gross margin53.4%-1.8pp
Operating margin-0.7%-0.3pp
Net margin0.1%0.0pp
FCF margin4.5%-0.8pp

Returns & leverage

See full
Return on equity0.2%+0.1pp
Debt / equity0.6×0.0×
Current ratio2.3×-0.4×

Where this comes from

Reported directly by Warby Parker in its filing.

Tagged under the XBRL concept us-gaap:DeferredTaxAssetsOperatingLossCarryforwards.

The official record: Warby Parker’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Warby Parker's deferred tax assets, operating loss carryforwards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Warby Parker's deferred tax assets, operating loss carryforwards?
Warby Parker (WRBY) reported deferred tax assets, operating loss carryforwards of $50.72M in Q4 2025.
How has Warby Parker's deferred tax assets, operating loss carryforwards changed year-over-year?
Warby Parker's deferred tax assets, operating loss carryforwards increased by 9.1% year-over-year, from $46.47M to $50.72M.
What is the long-term trend for Warby Parker's deferred tax assets, operating loss carryforwards?
Over 5 years (2020 to 2025), Warby Parker's deferred tax assets, operating loss carryforwards has grown at a 13.4% compound annual growth rate (CAGR), from $27.07M to $50.72M.